Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MBX Biosciences (MBX) Common Equity (2023 - 2026)

MBX Biosciences has reported Common Equity over the past 4 years, most recently at $437.8 million for Q1 2026.

  • Quarterly results put Common Equity at $437.8 million for Q1 2026, up 85.95% from a year ago — trailing twelve months through Mar 2026 was $437.8 million (up 85.95% YoY), and the annual figure for FY2025 was $369.2 million, up 43.42%.
  • Common Equity reached $437.8 million in Q1 2026 per MBX's latest filing, up from $369.2 million in the prior quarter.
  • Across five years, Common Equity topped out at $437.8 million in Q1 2026 and bottomed at -$97.9 million in Q2 2024.
  • Median Common Equity over the past 4 years was $235.4 million (2025), compared with a mean of $169.1 million.
  • The largest annual shift saw Common Equity skyrocketed 518.66% in 2024 before it surged 42.81% in 2025.
  • Over 4 years, Common Equity stood at -$72.5 million in 2023, then skyrocketed by 455.25% to $257.4 million in 2024, then surged by 43.42% to $369.2 million in 2025, then increased by 18.56% to $437.8 million in 2026.
  • Business Quant data shows Common Equity for MBX at $437.8 million in Q1 2026, $369.2 million in Q4 2025, and $387.5 million in Q3 2025.